Immunohistochemistry of normal mouse retina stained for vimentin (blue), synaptic vesicle marker SV2 (gold) and glycine transporter (red).
Image courtesy of Duke University.
SV Life Sciences
SV Life Sciences is a venture capital adviser and manager that invests selectively in businesses across the human life sciences sector, including biotechnology and pharmaceuticals, medical devices and instruments, and healthcare information technology and services. SV Life Sciences currently advises or manages five funds with capital commitments of approximately $2 billion primarily in North America and Europe. The firm invests in a broad range of companies including several ophthalmology companies in addition to Imagen Biotech such as Lux Biosciences, NeoVista, Neurotech, Ocular Therapeutix, Ophthotech and Panoptica. SV Life Sciences has a team of 32 professionals with diverse, complementary skills and experience that apply to almost any life sciences business. Established in 1993, SV Life Sciences has offices in Boston, San Francisco and London. For additional information, please visit www.svlsa.com.
Novo A/S is the holding Company of the Novo Group, and is wholly owned by the Novo Nordisk Foundation. Novo A/S was established in 1999 to manage the assets of the Foundation and actively make investments on behalf of the Foundation. The Novo Ventures team consists of six Partners in Copenhagen, one in London and two in San Francisco. With an evergreen structure, Novo A/S annually invests approximately $80-100 million in venture capital into private life sciences companies, and thus acts at a pace comparable to a traditional $350-400 million fund. In total Novo A/S has more than $10 billion under management, which includes significant shareholdings in the independently operating and publicly listed companies Novo Nordisk A/S and Novozymes A/S.
Fidelity Biosciences is a division of Fidelity Investments, one of the world's leading providers of financial services. For more than 30 years, Fidelity Investments has been a significant presence in the venture capital and private equity industry, investing the firm's own capital since 1969. This provides them with the flexibility, and capabilities of traditional venture capital firms while eliminating the additional pressures of fundraising. The result is a clear focus on building long-term value for Fidelity, their management partners, and co-investors. They are engaged investors and board members, seeking to add value by providing strategic guidance and assistance to management throughout the process of building successful businesses. They possess the energy and entrepreneurial spirit of a start-up enterprise, while bringing to bear the considerable strengths and resources of Fidelity Investments. For more information, please visit www.fidelitybiosciences.com.